Question explored with the scientific record
on ozempic3 months and still have stomach ache
Three months of stomach pain on Ozempic is not a trivial side effect. It is a signal that deserves investigation, not dismissal.
The evidence consistently shows gastrointestinal problems are the main side effect of semaglutide, the drug in Ozempic. In the SUSTAIN trials, about 4 in 10 people on the drug reported GI issues [7, 12]. Nausea, vomiting, and diarrhea are the most common [12]. A 2025 review found GI events in about 15 in 100 people, though that likely undercounts because it pools different studies [8]. The point is this: persistent pain at three months is within the known pattern, but it is not something to just "push through."
The bigger question is whether something more serious is happening. Case reports link semaglutide to acute pancreatitis, with one 48-year-old man developing severe abdominal pain and a lipase level near 5,000 after starting the drug [13]. Gallbladder events also appear in the safety data [12]. A 2025 study found that people with pre-existing GI disorders, alcohol use, and certain other diabetes drugs were more likely to have GI side effects [1]. If your pain is severe, radiates to your back, or comes with nausea or vomiting, that is an emergency evaluation, not a wait-and-see situation.
The evidence base here is thin on long-term answers. Most trials run a year or two [2, 9]. The manufacturer funded most of them. No one has studied what three months of continuous stomach pain means for your gut lining, your gallbladder, or your pancreas over years of use. The burden of proof is on the drug, and the drug has not met it for long-term GI safety. If the pain is interfering with your life, the reasonable move is to talk to your prescriber about stopping, lowering the dose, or investigating with imaging and labs. You do not owe a drug your comfort.
My call: persistent stomach pain at three months warrants a workup for pancreatitis and gallbladder disease, and stopping the drug is reasonable if the pain is significant. Confidence: moderate.
Sources used 7
-
Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
This retrospective single-center cohort study of 215 Chinese patients with type 2 diabetes mellitus found that pre-existing gastrointestinal disorders, alcohol consumption, and concurrent use of α-glucosidase inhibitors were independent risk factors for semaglutide-associated ga…
DOI: 10.3389/fendo.2025.1684395 -
Long Term Management of Obesity with Once Weekly Semaglutide Efficacy and Safety in Clinical Trials
Weekly semaglutide 2.4 mg yields substantial, durable weight loss in adults with overweight/obesity across STEP trials, with gastrointestinal adverse events as the main safety signal.
DOI: 10.52768/2995-5874/1029 -
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
This phase 3a trial demonstrated that once-weekly semaglutide 1.0 mg is superior to exenatide extended release 2.0 mg in improving glycemic control and reducing body weight in adults with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
DOI: 10.2337/dc17-0417 -
The Efficacy and Safety of Semaglutide-Based Medications for Long-Term Weight Loss and Cardiovascular Health
Systematic review of semaglutide-based medications for sustainable long-term weight loss and cardiovascular health, showing substantial weight loss (about 10–12 kg, BMI reductions ~2–3 units) and cardiovascular risk factor improvements across varied populations, with gastrointes…
DOI: 10.54393/pjhs.v6i4.2541 -
<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>
This article reviews the development, pharmacology, and clinical evidence for oral semaglutide in type 2 diabetes, detailing its efficacy (glycemic control and weight loss), cardiovascular safety (non-inferiority with potential mortality benefits in PIONEER-6), safety profile (G…
DOI: 10.2147/DMSO.S229802 -
Safety of injectable semaglutide for type 2 diabetes
A narrative safety review of injectable semaglutide for type 2 diabetes, synthesizing safety data from the SUSTAIN programme and related analyses, highlighting overall good safety with gastrointestinal effects, potential renoprotection, a signal for diabetic retinopathy risk lik…
DOI: 10.1080/14740338.2020.1772230 -
Semaglutide induced Pancreatitis
This case report discusses a 48-year-old male patient who developed acute pancreatitis after starting semaglutide, a glucagon-like peptide-1 receptor agonist, highlighting the potential risks associated with its use.
DOI: 10.36948/ijfmr.2024.v06i04.26238